Inactivated E. coli transformed with plasmids that produce dsRNA against infectious salmon anemia virus hemagglutinin show antiviral activity when added to infected ASK cells by Katherine GarcÃ­a et al.
ORIGINAL RESEARCH
published: 16 April 2015
doi: 10.3389/fmicb.2015.00300
Frontiers in Microbiology | www.frontiersin.org 1 April 2015 | Volume 6 | Article 300
Edited by:
Ricardo Flores,
Instituto de Biología Molecular y
Celular de Plantas (UPV-CSIC), Spain
Reviewed by:
Beatriz Navarro Ramirez,
Consiglio Nazionale delle Ricerche,
Italy
Francisco Tenllado,
Consejo Superior de Investigaciones
Científicas, Spain
*Correspondence:
Jaime Romero,
Laboratorio de Biotecnología, Unidad
de Alimentos, Instituto de Nutrición y
Tecnología de los Alimentos,
Universidad de Chile, Avenida El
Líbano 5524, Macul, Santiago, Chile
jromero@inta.cl
Specialty section:
This article was submitted to
Virology,
a section of the journal
Frontiers in Microbiology
Received: 02 December 2014
Accepted: 26 March 2015
Published: 16 April 2015
Citation:
García K, Ramírez-Araya S, Díaz Á,
Reyes-Cerpa S, Espejo RT, Higuera G
and Romero J (2015) Inactivated E.
coli transformed with plasmids that
produce dsRNA against infectious
salmon anemia virus hemagglutinin
show antiviral activity when added to
infected ASK cells.
Front. Microbiol. 6:300.
doi: 10.3389/fmicb.2015.00300
Inactivated E. coli transformed with
plasmids that produce dsRNA
against infectious salmon anemia
virus hemagglutinin show antiviral
activity when added to infected ASK
cells
Katherine García 1, Sebastián Ramírez-Araya 1, Álvaro Díaz 1, Sebastián Reyes-Cerpa 2,
Romilio T. Espejo 1, 3, Gastón Higuera 1 and Jaime Romero 1*
1 Laboratorio de Biotecnología, Unidad de Alimentos, Instituto de Nutrición y Tecnología de los Alimentos, Universidad de
Chile, Santiago, Chile, 2 Facultad de Química y Biología, Centro de Biotecnología Acuícola, Universidad de Santiago de Chile,
Santiago, Chile, 3Centro Nacional de Genómica y Bioinformática (Omics Solutions), Santiago, Chile
Infectious salmon anemia virus (ISAV) has caused great losses to the Chilean salmon
industry, and the success of prevention and treatment strategies is uncertain. The use
of RNA interference (RNAi) is a promising approach because during the replication
cycle, the ISAV genome must be transcribed to mRNA in the cytoplasm. We explored
the capacity of E. coli transformed with plasmids that produce double-stranded RNA
(dsRNA) to induce antiviral activity when added to infected ASK cells. We transformed
the non-pathogenic Escherichia coli HT115 (DE3) with plasmids that expressed highly
conserved regions of the ISAV genes encoding the nucleoprotein (NP), fusion (F),
hemagglutinin (HE), and matrix (M) proteins as dsRNA, which is the precursor of the
RNAi mechanism. The inactivated transformed bacteria carrying dsRNA were tested for
their capacity to silence the target ISAV genes, and the dsRNA that were able to inhibit
gene expression were subsequently tested for their ability to attenuate the cytopathic
effect (CPE) and reduce the viral load. Of the four target genes tested, inactivated E. coli
transformed with plasmids producing dsRNA targeting HE showed antiviral activity when
added to infected ASK cells.
Keywords: double-stranded RNA, infectious salmon anemia virus, bacterial delivery, antiviral, aquaculture
Introduction
In recent years, the Chilean salmon farming industry has grown into one of the major salmon
producers worldwide. However, the appearance of the infectious salmon anemia virus (ISAV)
has strongly affected the salmon industry, resulting in high mortality and substantial economic
losses (García et al., 2013). ISAV belongs to the genera Isavirus from the Orthomyxoviridae family
(Krossøy et al., 1999; Palese and Shaw, 2007). It possesses a segmented genome of single-stranded
RNA with negative polarity (Kulshreshtha et al., 2010) that encodes eight structural proteins and
two non-structural proteins (Cottet et al., 2011). Infection with ISAV principally affects Atlantic
salmon and other salmonid species (Raynard et al., 2001), causing systemic disease. The clinical
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and pathological signs of the disease can result in death (Evensen
et al., 1991), causing a strong decline in production with serious
economic costs. These losses are due to the limited availabil-
ity of effective vaccines and specific antiviral treatments (García
et al., 2013). To date, no effective pharmacological treatment has
been developed for this disease, and the success of prevention
strategies against ISAV is uncertain.
Considering the limitations of existing treatments, a plausi-
ble solution is the use of RNA interference (RNAi), which is
a very promising alternative against viral diseases (Peng et al.,
2005; Sarathi et al., 2008b; DeVincenzo et al., 2010). RNAi
is an intracellular process by which small interfering RNAs
(siRNAs) direct the degradation of matching messenger RNA
(mRNA) (Hammond et al., 2000; Provost et al., 2002; Hannon
and Conklin, 2004; Tijsterman and Plasterk, 2004; Gregory et al.,
2005), preventing its translation into protein and causing gene
silencing (Hammond, 2005). Effective delivery to the appro-
priate cells remains a major obstacle to successful RNAi. Sev-
eral strategies exist, from the delivery of naked siRNA duplexes
to more complex methods, including the systemic delivery of
siRNA complexes as conjugates (La Fauce and Owens, 2012)
and the use of non-pathogenic bacteria for delivery of dsRNA
(Sarathi et al., 2008a). Each approach has its advantages and dis-
advantages, which must be considered when choosing a deliv-
ery strategy. Recently, the development of RNAi therapies for
viral disease treatment has been suggested for aquatic organisms
(Lima et al., 2013). Successful reports have been published on
studies using RNAi technology against white spot syndrome virus
(WSSV) (Sarathi et al., 2008a,b), CyHV-3 virus (Gotesman et al.,
2014) and the virus that causes hemorrhagic septicemia, VHSV
(Ruiz et al., 2009; Kim and Kim, 2011; Kim et al., 2012). VHSV,
like ISAV, has a single-stranded RNA genome of negative polar-
ity (Kulshreshtha et al., 2010), which makes this strategy very
encouraging for our purposes.
In this work, we hypothesized that blocking the expression of
four structural viral genes, nucleoprotein (NP), which is bound in
multiple subunits to the genomic RNA (Palese and Shaw, 2007),
matrix protein (M), which constitutes the most abundant struc-
tural protein (Falk et al., 2004; Palese and Shaw, 2007), hemag-
glutinin (HE) (Falk et al., 2004; Müller et al., 2010) and fusion (F)
(Falk et al., 2004; Palese and Shaw, 2007), which are the surface
glycoprotein, would circumvent ISAV replication. To this end,
we explored the use of bacterially synthetized dsRNAs directed
against NP, F, HE, andM to prevent the synthesis of these proteins
by specific degradation of their respective mRNAs and decrease
the viral load and attenuation of CPE in ASK cells.
Materials and Methods
Cell Culture and Virus
Atlantic salmon kidney cells (ASK) were acquired from the
ATCC (ATCC R© CRL-2747) (Devold et al., 2000). Monolayers
of ASK were maintained at 15◦C in Leibovitz medium (L-15,
Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco),
penicillin (100U/ml, Gibco), streptomycin (100µg/ml, Gibco),
gentamycin (50µg/ml, US Biological) and β-mercaptoethanol
(55mM, Bio-Rad, USA). A viral inoculum stock of ISAV
genotype HPR35, with a titer of TCID50 = 107/mL, was kindly
provided by ADL diagnostics. The virus was propagated in
monolayers of 70% confluent ASK cells as described in the viral
infection section. All supernatants of the culture (aliquots of
virus) were stored at−80◦C.
Viral Infection
ASK cells were grown in 6-well plates to 70% confluence. At this
point, the cells were infected with a 1/10 dilution of viral stock
(TCID50 = 107) prepared in non-supplemented L-15 medium.
The virus was allowed to adsorb for 4 h. Then, the monolayer
was washed twice with phosphate-buffered saline (PBS), and sup-
plemented L-15 was added. The cells were incubated at 15◦C for
11 days post-infection (dpi) until the cytopathic effect (CPE) was
observed (Dannevig et al., 1995). At the end of infection, super-
natants of the culture were harvested and stored at −20◦C for
further analysis. The CPE observed during infection was followed
using an inverted Motic model EA31 microscope. Five visual
fields per well were recorded using a Motic cam 2500 and Motic
Image Plus 2.0 software.
Identification of Conserved Sequences in ISAV
Genes
Reference genomic sequences of the ISAV NP (NC_006502.1), F
(NC_006500.1), HE NC_006499.1), and M (NC_006497.1) genes
were identified inNCBI databases (http://www.ncbi.nlm.nih.gov/
genome). Each sequence was compared with the sequences in
GenBank using blastn (Altschul et al., 1990); the e-value param-
eter was adjusted to 1.10e−5, and the search was restricted to
sequences of the ISA virus taxa (txid: 55987) and Chilean isolates
(Table 1). The remaining parameters used were the default val-
ues. Groups of identified sequences were aligned using ClustalX
(Larkin et al., 2007), decreasing the penalties for the occurrence
of spaces and using the default input parameters. All alignments
were adjusted manually. Incomplete sequences or conflicts in
sequencing were eliminated from the analysis. From the align-
ment, a consensus sequence of 500 bp was searched for each
viral genomic sequence and selected for dsRNA design. Each of
these sequences was compared with the Salmo salar database (Di
Génova et al., 2011) to evaluate the off-target effects of the RNAi.
Construction of dsRNA-Producing Vectors
Targeting NP, F, HE, and M
Total viral RNA was extracted from 200µL of supernatants of
ISAV-infected ASK cells using the Total RNA Kit I (Omega
Biotek) according to the manufacturer’s instructions. cDNA was
synthetized as follows: 4µL RNA plus 1µL of random primer
(0.5mg/mL; Promega, USA) were heated for 5min at 70◦C.
Immediately after this step, 15µL of reverse transcription mix
was added (dNTPs, MgCl2, RNasin, 5X buffer, Improm-II RT;
Promega, USA), and the samples were incubated at 25◦C for
5min, 42◦C for 60min and 70◦C for 15min. To amplify the
500 bp conserved region that was previously selected, 3NP, 5F,
6HE, and 8M primers (Table 2), containing recognition sites for
the SacII or XhoI restriction enzymes, were used independently
for PCR amplification. The following thermal profile was used: 1
cycle of 5min at 95◦C, 30 cycles of 30 s at 95◦C, 30 s at 55◦C, and
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TABLE 1 | GeneBank accession of Chilean ISAV isolates sequences genes
used for the alignments in this study.
Viral segment GenBank accession
Nucleoprotein DQ520594.1; GU830905.1; GU830897.1
Fusion protein FJ592146.1; FJ592163.1; EU449765.1; GU830899.1;
FJ592162.1; FJ592165.1; EU130923.1; EU849005.1;
EU849011.1; FJ592140.1; FJ592143.1; EU449768.1;
EU849007.1; EU449767.1; EU552491.1; FJ592142.1;
FJ592150.1; EU849006.1
Hemagglutinin protein EU849018.1; GU830900.1; FJ594303.1; FJ594301.1;
FJ594326.1; FJ594317.1; EU851043.1; EU271682.1;
EU849012.1; EU849015.1; EU625681.1; EU625675.1;
FJ594325.1; EU849017.1; EU625677.1; FJ594319.1;
EU625668.1; FJ594296.1; EU625678.1; EU625674.1;
FJ594323.1; EU625671.1; EU849016.1; JQ712975.1;
EU849013.1; EU849014.1; FJ594297.1; EU625676.1;
EU625669.1; EU625670.1; FJ594285.1; FJ594328.1;
EU625667.1; FJ594292.1; FJ594332.1; EU625679.1;
FJ594306.1; FJ594315.1; GU830908.1; EU65672.1;
FJ594316.1; FJ594295.1; EU625666.1; FJ594294.1;
EU625680.1; FJ594284.1; FJ477897.1
Matrix protein AF312315.1; GU830902.1; GU830910.1
30 s at 72◦C and a final extension of 10 s at 72◦C. Subsequently,
each PCR product was cloned into pGEMT easy (Promega,
USA), cut simultaneously with the SacII (New England Bio-
labs, USA) and XhoI (New England Biolabs, USA) restriction
enzymes and ligated into the L4440 vector (graciously donated
by Cold Spring Harbor Laboratory, NY, USA), which contains
T7 promoter sites flanking each side of the multiple cloning
site (MCS). L4440 plasmids carrying NP, F, HE, orM fragments
were sequenced in Macrogen (USA) to confirm the sequence
and subsequently electroporated into Escherichia coli bacterial
strain HT115 (DE3), an RNase III-deficient non-pathogenic
strain (graciously donated by Cold Spring Harbor Laboratory,
NY, USA).
Production and Quantitation of Antiviral dsRNA
E. coli HT115 (DE3) carrying L4440 vectors with NP, F, HE
orM inserts were grown in 10mL of LB medium supple-
mented with 100µg/mL ampicillin (Winkler, Chile). Induction
of double-stranded RNA (dsRNA) was performed with 2mM
IPTG (Invitrogen, USA) for 4 h, and a total nucleic acid extrac-
tion was performed. The bacterial pellet was resuspended in
5mL of 70% ethanol in PBS, incubated at room temperature for
5min and collected by centrifugation at 6000 g for 5min at 4◦C.
Then, the bacterial pellet was resuspended in 1mL of 150mM
NaCl (Winkler, Chile) and incubated at room temperature for 1
h; the centrifugation was then repeated for 10min. The super-
natant was collected, and the genetic material was allowed to
precipitate at −20◦C overnight. Afterwards, the supernatant was
centrifuged for 30min at 13000 g at 4◦C, and the formation of
a white pellet was observed (Posiri et al., 2013). These nucleic
acids were treated with 1µL RQ1-RNase free DNase (Promega,
USA) and 8M lithium chloride (Winkler, Chile) to precipitate
and remove any single-stranded RNA. Finally, the samples were
treated with 8M lithium chloride to precipitate the dsRNA. To
finish, dsRNA was resuspended in 170µL nuclease-free water
(Winkler, Chile). The purified dsRNA was quantified using the
DNA 1000 LabChip R© kit on a Bioanalyzer Agilent 2100 (Agi-
lent Technologies, USA). To verify the identity of cloned dsRNA,
purification of each dsRNA from a 1% w/v agarose gel was per-
formed. Each dsRNA (1µL) was used to synthesize cDNA as
described above. Subsequently, conventional PCRwas performed
using primers NPi, Fi, HEi, and Mi to amplify an internal section
of the conserved regions of ISAV. The thermal profile used was 1
cycle of 5min at 95◦C, 30 cycles of 30 s at 95◦C, 30 s at 55◦C, and
30 s at 72◦C and a final extension of 10 s at 72◦C.
Bacterial Co-Localization Assay
ASK cells were seeded into a 24 well-plate at a density of 1× 105
cells/well. After 2 days, the cells were incubated for 40min with
the fluorescent probe CellTracker™ Orange CMRA (Invitrogen,
USA) at a final concentration of 10µM. Then, the cells were
washed three times with PBS and treated with attenuated E.
coli HT115 (carrying the green pBADT plasmid) overexpressing
green fluorescent protein (GFP) in supplemented L-15 media at
a multiplicity of infection (MOI) of 500 bacteria/cell (the max-
imum MOI that did not cause cell damage). Attenuation of the
bacterial culture was performed by adding formaldehyde at a final
concentration of 0.5% v/v and incubating for 20min at room
temperature. Immediately after this step, the bacterial culture was
centrifuged and washed twice with PBS, quantified in a Petroff-
Hausser chamber and used for analysis. The incubation of ASK
cells with attenuated bacteria in supplemented L-15 media was
followed by 4 days at 15◦C. During the assay, slides with cell sam-
ples were removed at 0, 24, 48, and 96 h. Each slide was fixed
with 4% paraformaldehyde (PFA) for 10min and then treated
with 50mM NH4Cl for 10min. Finally, the slides were mounted
in 1,4-diazabicyclo[2.2.2]octane (DABCO) and visualized using
a Nikon C2+ confocal microscope. Phase contrast photographs
were taken using a Carl Zeiss LSM 510 confocal microscope with
a DIC 3.4 filter.
Antiviral Treatment in ISAV-Infected ASK Cells
ASK cells were grown in 6-well plates to 70% confluence. Then,
the cells were infected with ISAVHPR35 and treated individually
with attenuated E. coli HT115 carrying dsRNA against HE, NP,
M, or F individually or in a mixture of equal proportions. Addi-
tionally, a treatment with attenuated E. coli carrying an empty
pL4440 vector was included. In all cases, we used a MOI of
500 (bacteria/cell) because it was the maximum MOI that did
not cause cell damage. The attenuation process was the same
as described above (in the bacteria co-localization assay). Cells
that underwent different treatments were harvested at 11 dpi
and incubated in EDTA-free protease inhibitor buffer (Roche,
USA). These samples were used for real-time PCR and western
blot analyses. In parallel, the supernatants were collected and
used to determine the viral titer using a viral plaque assay. The
CPE observed during each treatment was followed in an inverted
Motic model EA31 microscope and recorded photographically
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TABLE 2 | List of the primers used in this study.
Primer Experimental protocol Primer orientation Sequence Product length (bp) References
3 NP Cloning Sense CCGCGGAGCTTTCTGATTGACCCACCT 480 This work
Antisense CTCGAGAAGCATCTCCCTGATAGCGC Cottet et al., 2010
5 F Cloning Sense CCGCGGCCAAATGCGGGAGGAAAGGA 450 This work
Antisense CTCGAGCTCCTGGGAATGCTCTCTGG This work
6 HE Cloning Sense CCGCGGCTGCAGGCCAAAAACGGAAA 492 This work
Antisense CTCGAGGGTTCCCCTCACTTCAAAGGT This work
8M Cloning Sense CCGCGGTGCTACTTACACTTGGCGGG 451 This work
Antisense CTCGAGCCCAGGAGCACCATCTTCTC This work
3 NPi PCR Sense CAATGGTTGCAACAGCATTC 205 This work
Antisense ACTTGCCAGCTTCGATCTGT This work
5 Fi PCR Sense ATCTGCGGAGGTACAACAGG 224 This work
Antisense ACCAGTACAGGCGATGGAAC This work
6 HEi PCR Sense ACTTGGGAACCAATGACTGC 182 This work
Antisense ACCGGTAATTGCGTCTGTTC This work
8 Mi PCR Sense GAAAGATCCACCGTCTGGAA 200 This work
Antisense TCTGCATCCTGCTGTGTAGC This work
3 NPq qPCR Sense ATGGCCGATAAAGGTATG 348 This work
Antisense TTGTTGTCAACCATGCCAC This work
5 Fq qPCR Sense CTGTTGCACTCAGCATGGAT 257 This work
Antisense CTCCTGGGAATGCTCTCTGG This work
6 HEq qPCR Sense GGCACGATTCATAATTTTATTCC 223 This work
Antisense TGAAGCAGATGAGTGGAAGG This work
8 Mq qPCR Sense TGGATACAAAAACATCTACCATGC 200 This work
Antisense TGGTTCAAGGTTTTGACTTTCAC This work
Mx qPCR Sense CTGGAGGAACCAGCAGTCAA 273 Abid et al., 2013
Antisense TAAGGGTCGGTCGTCTTCCT
ILA qPCR Sense GGCTATCTACCATGAACGAATC 155 Mjaaland et al., 2002
Antisense GCCAAGTGTAAGTAGCACTCC
β-actina qPCR Sense CCAAAGCCAACAGGGAGAAG 91 Olsvik et al., 2005
Antisense AGGGACAACACTGCCTGGAT
using aMotic cam 2500; five visual fields were randomly analyzed
with Motic Image Plus 2.0 software.
Real-Time qPCR Analysis
The procedure for total RNA extraction and cDNA synthesis
was the same as described above except we used primer pairs
NPq, Fq, HEq, and Mq (Table 2) instead of random primers. To
estimate the mRNA expression levels of NP, F, HE, and M, real
time RT-PCR was carried out using the Corbett Rotor-Gene 6000
Thermal Cycler (Corbett Life Science) according to the manu-
facturer’s instructions and using Rotor-Gene Version 1.7.87 soft-
ware. All reactions were performed in triplicate. The PCR primer
pairs NPq, Fq, HEq, Mq and the control gene β-actin (Olsvik
et al., 2005) are shown in Table 2. The PCR reactions were per-
formed in a final volume of 10µL using Light Cycler R© 480 SYBR
Green I Master Mix (Roche, USA) with 1µL of cDNA and 1µL
of each 50mM primer. The thermal profile of real-time qPCR
was as follows: hold for 1 cycle of 5min at 95◦C followed by
40 cycles of 15 s at 95◦C, 10 s at 55◦C and 10 s at 72◦C and a
final hold of 1min at 40◦C. Relative amounts of each viral tran-
script are expressed as the fold change in log2 of NP, F, HE, orM
in infected cells treated with bacteria carrying antivirals com-
pared to infected cells without antiviral treatment. To estimate
the mRNA expression levels of Mx reactions were carried out
under the same conditions previously mentioned. All reactions
were performed in triplicate. All data were normalized to β-actin
expression.
Western Blot Analysis
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) was performed using 15µg of protein from each sam-
ple on a 4–12% NuPAGE Bis-Tris Gel (Bio-Rad, USA). The
proteins were blotted onto polyvinylidene difluoride (PVDF)
membranes, blocked with 5% dry milk and incubated at 4◦C
overnight with anti-HE antibody (clone 8D2/E9; GrupoBios,
Bios-Chile) diluted 1:2000 or anti-β-actin antibody (clone AC-
74, Sigma-Aldrich) diluted 1:500, followed by a 1 h incubation
with the secondary antibody [rabbit-anti-mouse horseradish per-
oxidase (HRP), Invitrogen, USA] at a dilution of 1:20000. The
blots were developed using Novex R© ECL HRP Chemilumines-
cent Substrate (Invitrogen, USA) and exposed to Carestream
Kodak Biomax Light film (sigma Aldrich, USA). The films were
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scanned and used for expression analysis with ImageJ 1.43µ
software.
Viral Plaque Assay
The viral titre of the supernatant from ASK culture infected with
ISAV HPR35; ASK infected and treated with attenuated E. coli
HT115 carrying plasmid L4440 or ASK infected and treated with
attenuated E. coli HT115 carrying dsRNA against HE, was deter-
mined with a plaque assay (Castillo-Cerda et al., 2014). ASK cells
were seeded into 12-well plates and incubated for 3 days at 15◦C.
Then, the culture mediumwas removed from the monolayer, and
500µL of supernatant containing virus, ten-fold serially diluted,
from different conditions (ISAV HPR35, ISAV HPR35 infec-
tion + E. coli HT115 pL4440 or ISAV HPR35 infection + E.
coli HT115 dsRNA HE) or 500 uL of supernatant from unin-
fected ASK culture (ASK control) were added. After 4 h at 15◦C,
the inoculum was removed, and 3mL of semi-solid medium was
added to each well. The plates were incubated for 10 days post-
infection at 15◦C. At day 10 post-infection, the cells were fixed
in 1mL of formalin (37%) for 1 h at 25◦C, and the semi-solid
medium was removed. For visualization, 2mL of crystal violet
(1%) was added for 1 h at 25◦C, and the excess crystal violet was
removed. Finally, the number of lysis plaques formed in wells was
counted for each antiviral treatment.
Statistical Analysis
All experiments were performed in triplicate. The data were ana-
lyzed using GraphPad v. 5.01. Real-time PCR data were analyzed
using Rest 2009 software. Protein expression data were analyzed
using an ANOVA with Bonferroni’s multiple comparison post-
test. Viral plaque assay data were analyzed using the Wilcoxon
test.
Results
dsRNA Design and Production
Identification of Conserved Regions of Four Genes
Involved in the Viral Cycle of ISAV (NP, F, HE, and M)
To appropriately design the dsRNA sequences, one 500 bp con-
served region (Supplementary Table 1) was identified in the
alignment of the Chilean ISAV isolates considered in this study
(Table 1) for each of the four viral genes NP, F, HE, and M.
The characteristics of these conserved sequences are described in
Table 3. Note that the sequence identity (∗) was the percentage
of nucleotide of sequences that had the same residue at the same
position in the alignment.
Detection and Quantitation of dsRNA Produced in E.
coli HT115 (DE3)
The production of each dsRNAwas observed in a 1% w/v agarose
gel as one band of approximately 500 bp. These bands were puri-
fied, and conventional PCR reactions of the internal regions
of the conserved sequences were performed. The expected size
was observed for each purified dsRNA, with bands of 205, 224,
182, and 200 bp for NP, F, HE, and M, respectively, demonstrat-
ing successful expression (Supplementary Figure 1A). Further-
more, dsRNAs were visualized and quantified in a bioanalyzer
(Supplementary Figure 1B). The concentration of each band was
used to calculate the number of dsRNA copies produced by each
milligram of bacteria. Values of 2.44×1013, 6×1013, 2.41×1013,
and 7.87 × 1013 copies of dsRNA/mg bacteria were obtained for
NP, F, HE, and M, respectively.
Delivery of dsRNA into ASK Cells
Co-Localization Assay of E. coli HT115 (DE3)
Overexpressing GFP in ASK Cells
E. coli HT115 (DE3) overexpressing GFP was used in an attempt
to evaluate the endocytosis of these bacteria after treatment
with formaldehyde. Green E. coli HT115 (DE3) were observed
near ASK cell membranes at 24 h post-incubation with bacteria
(Figure 1, upper left panel) but were not uptaken, as observed
TABLE 3 | Analysis of each conserved sequence of four genes of ISAV.
Genomic Size of Nucleotide position Sequence
segment genomic of conserved identity %*
segment (bp) sequence (start-term)
Nucleoprotein 1800 1076–1575 89.2
Fusion 1367 335–834 99.5
Hemagglutinin 1182 1–500 99.4
Matrix 861 95–594 92.7
FIGURE 1 | Co-localization assay of E. coli HT115 expressing GFP in
ASK cells. Green E. coli were added to ASK cells stained with fluorescent
orange dye. Phase contrast (upper panel) and fluorescence (lower panel)
confocal microscopy images were taken at 24 h (left) and 48 h (right). Bacteria
were visualized as orange/yellow when they co-localized with the orange
fluorescent probe in the cell cytoplasm, as indicated with arrows at 48 h in the
right bottom panel and an asterisk in the enlarged panel. Scale bars represent
10µm.
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when a cytoplasmic probe was used in co-localization assays
(Figure 1, bottom left panel). At 48 h post-incubation, a few bac-
teria (1 or 2/cell) were present as an orange/yellow mark in
conjunction with GFP fluorescence, indicating co-localization
with ASK cytoplasm (Figure 1, arrows and asterisks in bottom
right panel), suggesting the internalization uptake of bacteria.
These data were confirmed using a Z-plane reconstruction (data
not shown). This phenomenon was also observed at 96 h post-
incubation with bacteria, although no increase in the number of
uptaken bacteria per cell was observed (data not shown).
Effect of dsRNA
Effect of dsRNA Targeting NP, F, HE, orM on the
Expression of Their Gene Targets
To evaluate whether dsRNAs produced by E. coli HT115 were
able to decrease the expression of viral genes, infected ASK cells
were treated with bacteria expressing each dsRNA (NP, F, HE,
or M) independently, expressing all of the dsRNAs together in
equal concentrations (NP/F/HE/M) or not expressing dsRNA.
For purposes of comparison, the relative expression of viral
genes in control (ISAV HPR35) and treated ASK cells (ISAV
HPR35 + dsRNA) were measured. Relative amounts of each
viral transcript are expressed as the fold change in NP, F, HE,
orM in infected cells treated with bacteria carrying the antivi-
ral, compared to infected cells without antiviral treatment. All
data were normalized to β-actin expression. The expression levels
of NP, F, andM mRNAs were not significantly affected by treat-
ment with their specific dsRNAs (Figure 2A). However, mRNA
expression of the gene encoding HE was significantly reduced
(six-fold change in log2) by dsRNA against HE (Figures 2A,B).
HE mRNA expression was not affected when infected ASK
cells were treated with empty vector (no dsRNA, pL4440) and
decreased to a lesser degree (1-fold change in log2) when the
cells were treated with a combination of equal parts of the bacte-
ria carrying their corresponding dsRNAs (dsRNA NP/F/HE/M)
(Figure 2B).
Effect of dsRNA against HE on HE Protein Expression
HE protein expression was significantly decreased by 45% in
infected ASK cells using dsRNA against HE (dsRNA HE)
compared with infected and non-treated cells (ISAV HPR35)
(Figure 3), by western blot analysis. On the other hand, HE
protein expression in infected ASK cells treated with bac-
teria carrying equal amounts of dsRNA against NP, F, HE,
and M (dsRNA NP/F/HE/M) or with empty bacteria (pL4440)
was unaltered compared with the ISAV-infected control (ISAV
HPR35).
The Effect of HE dsRNA on the ISAV Viral Load in
ASK Cultures
To assess whether the decrease in the HE protein level correlated
with a lower number of infectious viral particles, a viral plaque
assay was performed. The viral titer (PFU/mL) in the supernatant
of infected ASK cells treated with dsRNA against HE (dsRNAHE;
5.9×103 PFU/mL) was 24-fold lower than the viral titer in super-
natants of non-treated cells (HPR35, 1.4×105 PFU/mL). Bacteria
carrying no dsRNA (pL4440) had no significant effect on ISAV
viral titer (Figure 4). An uninfected cell control (ASK) was added
to verify that cells did not form lysis plaques for other reasons
(Figure 4).
FIGURE 2 | Relative expression of viral mRNA in infected ASK
cells treated with different dsRNAs. (A) Relative viral mRNA
expression of NP, F, HE, and M in ASK cells infected with
ISAV HPR35 and treated with HT115 E. coli carrying dsRNA
against NP (dsRNA NP), F (dsRNA F), HE (dsRNA HE), orM
(dsRNA M). Data were compared with viral mRNA expression of
infected but non-treated ASK cells and expressed as fold change
in log2. (B) Relative expression of HE mRNA in ASK cells
infected with ISAV HPR35 and treated with HT115 E. coli
carrying dsRNA against HE (dsRNA HE), a mixture of the four
E. coli strains carrying each of the dsRNAs (dsRNA NP/F/HE/M)
or E. coli carrying the empty vector (pL4440) compared with
viral mRNA expression in infected but non-treated ASK cells.
Data are expressed as fold change in log2. Bars represent the
average results (n = 3), and the error bars represent standard
errors of the means (SEM). (***) indicates significant differences
between treated, infected ASK cells vs. untreated, infected ASK
cells, p < 0.05. **indicates significant differences between
NP/F/HE/M-mix treated, infected ASK cells vs. HE treated,
infected ASK cells, p < 0.05.
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FIGURE 3 | Expression of HE protein in infected ASK-cells treated with
dsRNA. Lysates from ASK cells infected with HPR35 ISAV, infected ASK cells
treated with E. coli HT115 carrying dsRNA against HE (dsRNA HE), the dsRNA
NP/F/HE/M mixture or empty vector (pL4440) were analyzed by western blot
using HE-antibody for viral protein detection. All data were normalized to
β-actin expression (HE/β-Actin). Bars represent the average result (n = 3), and
the error bars represent standard errors of the means (SEM). (**) indicates a
significant difference between infected ASK cells treated with dsRNA against
HE (dsRNA HE) vs. ASK infected cells (ISAV HPR35), and infected ASK cells
treated with the empty vector (pL4440), p < 0.05.
The Effect of HE dsRNA on the CPE of ISAV in ASK
Cultures
Microscopic observations revealed characteristic phenotypic
changes when ASK cells were infected with ISAV HPR35.
At day 11 post-infection, infected cells showed an exten-
sive CPE with numerous vacuolated and stellated-shaped cells
with partial monolayer detachment (Figure 5B). In contrast,
when infected cells were treated with HE dsRNA, the cells
showed decreased CPE, no vacuolated cells and less monolayer
detachment (Figure 5C). In infected cells treated with bacteria
expressing no dsRNA against HE, the cellular damage observed
was similar to that upon infection with ISAV with no additional
treatment (Figure 5D). As a control, ASK cells after 11 days of
cultivation are shown in Figure 5A.
The Effect of dsRNAs on Mx Expression in ASK
Cultures
To evaluate the ability of dsRNAs produced by E. coli HT115
to induce expression of Mx, a marker of the interferon
pathway, uninfected ASK cells were treated with bacteria
expressing each dsRNA (NP, F, HE, or M) independently
or expressing no dsRNA (empty vector pL4440). All gene
expression data were normalized to β-actin expression.
The expression levels of Mx mRNAs were significantly
FIGURE 4 | Effect of HE dsRNA on viral titer (PFU/mL) in the
supernatants of infected ASK cells. Viral titers (PFU/mL) of ISAV in the
supernatants of ASK cells infected with ISAV HPR35 (HPR35), infected ASK
cells treated with E. coli HT115 carrying dsRNA against HE (dsRNA HE) or
empty vector (pL4440). The supernatant of uninfected cells was added as an
assay control (ASK). Bars represent the average result (n = 3), and the error
bars represent standard errors of the means (SEM). (*) indicates a significant
difference between HPR35-infected ASK cells treated with dsRNA against HE
(dsRNA HE) vs. infected ASK cells (HPR35), p < 0.05.
FIGURE 5 | The effect of HE dsRNA on induced CPEs in infected ASK
cells. (A) Uninfected ASK cells at 11 days post-infection (B) ASK cells
infected with HPR35 ISAV without treatment and (C) with the addition of E. coli
carrying dsRNA against HE. (D) Infected ASK cells and treatment with E. coli
HT1115 carrying empty vector pL4440 was included as a control. The CPEs
observed in ASK cells infected as described were vacuolated cells and
monolayer detachment. The scale bar represents 20µm.
induced at similar extent by all dsRNAs (Supplementary
Figure 2).
Discussion
RNAi is a promising methodology for developing new therapeu-
tic and antiviral strategies (Gavrilov and Saltzman, 2012). RNAi
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has been suggested for the development of therapies aimed at
the treatment of viral diseases and parasites in aquatic organisms
(Lima et al., 2013), with successful reports on studies using RNAi
against numerous viruses that cause problems in aquaculture.
Sarathi et al. (2008b) were the first to show the antiviral ability of
bacterially synthetized dsRNAs. They revealed that Vp28 dsRNA
produced in bacteria was able to silence VP28 gene expression in
WSSV. Similarly, others studies in vitro (Kim andKim, 2011; Kim
et al., 2012) have revealed that it is possible to control the virus
causing viral hemorrhagic septicemia (VHSV), a single-stranded
RNA genome virus that causes important viral diseases in a wide
variety of wild and cultured fish species worldwide (Kim et al.,
2012), using dsRNA antivirals in EPC (Epithelioma papulosum
cyprinid) and CHSE214 (chinook salmon embryo) cells. Addi-
tionally, Kim and colleagues showed that long dsRNA antivirals
are able to reduce the expression of the VHSV G gene, which
encodes a glycoprotein, in a manner that is dependent on RNAi
because they do not activate the interferon pathway (Kim et al.,
2012). Later studies showed the feasibility of using RNAi ex vivo
to inhibit the viral replication of cyprinid herpesvirus-3 (CyHV-
3) in cultured cells (Gotesman et al., 2014). Some of these success-
ful studies support the methodology utilized in this study, which
was based on the use of long bacterially synthesized dsRNAs, to
inhibit replication of ISAV ex vivo by impairing the expression
of viral proteins. To our knowledge, this is the first experimental
approach using RNAi against the ISA virus. We searched con-
served genomic regions within sequences of Chilean isolates that
were available in the database (Table 1). Despite the few avail-
able sequences found for the NP andM genes, one conserved
genomic region of 500 bp was detected in all genes of interest.
Once we had designs for dsRNA, we used E. coli HT115 (DE3)
for production and delivery of dsRNA because it is a good option
for large-scale production and in vivo delivery in aquaculture
systems (Sarathi et al., 2008a). These bacteria have been widely
used for production and delivery of dsRNAs in other study mod-
els, such as C. elegans (Timmons and Fire, 1998; Kamath et al.,
2001; Timmons et al., 2001). However, we observed that only
one or two bacteria co-localized with the cytoplasm of ASK cells
in our co-localization assay, suggesting that few bacteria were
uptaken.We confirmed these observations performing PCR anal-
ysis of viral HE sequence using DNA preparations fromASK cells
treated with attenuated bacteria (Supplementary Figure 3). These
results agree with an observation by Simon and Leong (2002),
who rarely observed gene transfer into CHSE-214 cells, another
salmon-derived cell line, when using E. coli as a vector. Addi-
tionally, Grillot-Courvalin and colleagues observed that fewer
than 0.1% of CHO cells (derived from Chinese hamster ovaries)
received gene transfer when E. coliwas used as a vector. However,
when invasive E. coli were used, 6% of cells were found to be pos-
itive, indicating successful gene transfer (Grillot-Courvalin et al.,
1998). Invasive E. coli have been found to act as a good gene deliv-
ery system in both phagocytic and non-phagocytic mammalian
cells (Grillot-Courvalin et al., 1999), showing that using inva-
sive non-pathogenic bacteria is a plausible strategy by which to
obtain better uptake and delivery results. Despite the low num-
ber of uptaken bacteria in our experiments, the silencing effi-
ciency of the four bacterially expressed dsRNAs against the NP,
F, HE, andM genes was investigated. The dsRNA against HE was
found to significantly reduce mRNA expression. This result indi-
cates that despite the low number of bacteria entering cells, the
dsRNA input was sufficient to act in the ASK cells and specifi-
cally inhibit the expression of HE mRNA. It draws attention the
fact of the mRNA expression of the gene encoding HE was sig-
nificantly reduced (six-fold change in log2) by dsRNA against
HE, but it decreased to a lesser degree (1-fold change in log2)
when the cells were treated with a combination of equal parts
of the bacteria carrying their corresponding dsRNAs (dsRNA
NP/F/HE/M). Similarly, HE protein expression was significantly
decreased by 45% in infected ASK cells using dsRNA against
HE (dsRNA HE) compared with infected and non-treated cells
(ISAV HPR35) but HE protein expression in infected ASK cells
treated with bacteria carrying equal amounts of dsRNA against
NP, F, HE, andM (dsRNA NP/F/HE/M) was unaltered compared
with the ISAV-infected control. These findings strongly suggest
a dose-dependency effect of dsRNA against HE in the assays. In
addition, the absence of an effect on the HE mRNA level dur-
ing the treatment with bacteria carrying empty L440 suggest that
the inhibition of HE gene transcription was a response of the
RNAi machinery induced by dsRNA against HE. However, this
response seems to be combined with non-specific effects, since
the expression of Mx gene (involved in the interferon pathway)
is activated when non-infected ASK cells are treated with atten-
uated bacteria expressing dsRNA (data not shown). The fact that
some dsRNA induces sequence specific antiviral activity in addi-
tion to non-specific immunity is not new, and it has been pre-
viously observed by other authors (LaFauce and Owens, 2009).
dsRNA against HE was able to induce specific effect decreasing
HE mRNA and consequently, decreasing HE protein expression.
In contrast, dsRNA against NP, F, M had no effect decreasing the
expression of their target viral proteins. This could be due to a
limited uptake of bacteria by ASK cells. However, bacteria car-
rying the other dsRNA (against NP, F, and M) are also isogenic;
among them the only difference is the insert, even insert size
is∼500 bp in all cases. Furthermore, the number of dsRNA copies
permg of bacteria is very similar ∼1013 copies of dsRNA/mg
bacteria in all cases. For this reason, we believe unlikely that
differences in the antiviral effects were based on different bac-
terial uptake. The other reason may be explained by differences
in the insert. It was reasonable that the target mRNAs for the
other dsRNA molecules tested (NP, F, and M) were not silenced
because other studies have shown that the degree of protection
afforded by specific dsRNAs, varies between different targeted
viral genes. The degree of protection conferred by dsRNA is well-
known to depend on the target viral gene (Robalino et al., 2005).
In this work, we selected ISAV structural proteins as candidates
for silencing. Some works have compared differences in silenc-
ing non-structural and structural protein genes and found no
clear differences (Flores-Jasso et al., 2004; Sanjuktha et al., 2012).
However, Sanjuktha and colleagues showed that the function of
the encoded protein is a more important criterion for selection
(Sanjuktha et al., 2012). Moreover, the gene silencing effect of
dsRNA is likely to vary substantially with the targeted position
on the mRNA (Luo and Chang, 2004). Robalino et al. (2005)
reported that different mRNAs were differentially susceptible to
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sequence-dependent targeting. Until now, the reasons for the dif-
ferences in RNAi efficacy have not been well-understood, but they
may involve primary sequence and secondary structure proper-
ties of dsRNA and targeted viral mRNAs. Additionally, the bind-
ing of viral and/or cellular proteins to the targeted RNA sequence
may prevent recognition by the RNA-induced silencing complex
(Hasnoot et al., 2003).
The strong decrease in the HE mRNA level was reflected in
a 45% decrease in protein expression, although the significant
reduction in mRNA when all antivirals were used together, was
not reflected in a significant protein reduction. These results
likely occurred due to the high stabilization of the remaining
mRNA, as has been shown in other viruses, such as equine
infectious anemia virus (Martarano et al., 1994) and rabies virus
(Palusa et al., 2012). Nonetheless, the decrease in the protein level
in 45%, was associated with a strong decrease in the viral titer,
which decreased by 24-fold. This effect was probably due to the
combined response of RNAi pathway with non-specific effects
induced in a sequence-independent manner, since the expres-
sion of Mx gene is activated in uninfected ASK cells treated
with dsRNA against HE (Supplementary Figure 2). However, Mx
expression was induced at similar extent by dsRNA HE and the
other dsRNA molecules, which had no antiviral effect, hence,
we suggest that the inhibition of HE gene transcription and the
decrease in the viral titer occur mainly due to specific effects
of dsRNA HE treatment. Concomitantly, the lower number of
infective viral particles was reflected in a minor CPE in infected
ASK cells, and cells with hallmark morphologic changes (vac-
uolated cells) and monolayer detachment associated with viral
infection were not observed. These effects are not specific to ISAV
because the same phenomenon has been observed when gene
expression is silenced ex vivo using RNAi against other viruses.
In the case of goatpox, a decline in the number of infective viral
particles was reflected in a reduced CPE in Vero cells (Zhao
et al., 2012). A similar result was observed when RNAi was used
against the equine encephalitis virus in Vero cells and U87MG;
all effective RNAi silencing of the target gene decreased the CPE
associated with viral infection (Lundberg et al., 2013).
The results obtained in this work using an ex vivo model
support for the first time the possible use of RNAi against the
ISA virus. However, the administration of RNAi in vivo is still
a substantial challenge. Some reports have already studied the
efficacy of RNAi administered in vivo (LaFauce and Owens,
2009). These studies have shown that RNAi confers protective
effects by slightly reducing the viral titer of Penaeus merguiensis
densovirus, and it has a large effect on the prevention of mortality
in treated crickets (LaFauce and Owens, 2009). This fact indicates
that protective non-specific effects likely occur in some instances
of RNAi, as we also observed with dsRNA against HE.
Conclusion
In light of the results presented, we demonstrated that long
dsRNA against HE elicits the RNAi process in salmon cells, and
these dsRNA molecules are able to reduce ISAV replication and
viral load in infected ASK cells. Although it seems that dsRNA
also induces non-specific effects of the immune response. This
strategy could still be improved and optimized, leading us to
design new methodologies in the future using in vivo models to
provide an efficient tool for ISAV control in cultured fish.
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